Development of a weighted scale to assess the quality of cost-effectiveness studies and an application to the economic evaluations of tetravalent HPV vaccine

Journal of Public Health

Volumn 19, Issue 2, 2011, Pages 103-111

  La Torre, Giuseppe ^a,b   Nicolotti, Nicola ^a   De Waure, Chiara ^a   Ricciardi, Walter ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Costs and cost analysis; Health technology assessment; Papillomavirus vaccines; Quality

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CHECKLIST; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; ECONOMIC EVALUATION; INFORMATION PROCESSING; QUALITY CONTROL; STUDY DESIGN;

EID: 79957986345     PISSN: 09431853     EISSN: 16132238     Source Type: Journal    
DOI: 10.1007/s10389-010-0377-z     Document Type: Article

References (38)

1. Bergeron C, Largeron N, McAllister R, Mathevet P, Remy V (2008) Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France. Int J Technol Assess Health Care 24:10-19 (Pubitemid 351158538)
2. Beutels P, Thiry N, Van Damme P (2007) Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination-a review (2002-2006). Vaccine 25:1355-1367 (Pubitemid 46074293)
3. Boot HJ, Wallenburg I, de Melker HE et al (2007) Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands. Vaccine 25:6245-6256 (Pubitemid 47096668)
4. Brisson M, Van de Velde N, De Wals P, Boily MC (2007) The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 25:5399-5408 (Pubitemid 46977529)
5. Centre for Reviews and Dissemination 2009) Systematic reviews. CRD, University of York, York
6. Chesson HW, Ekwueme DU, Saraiya M, Markowitz LE (2008) Costeffectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis 14:244-251 (Pubitemid 351213674)
7. Chiou CF, Hay JW, Wallace JF et al (2003) Development and validation of a grading system for the quality of cost-effectiveness studies. Med Care 41(1):32-44
8. Dasbach E, Insinga R, Elbasha E (2008) The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. BJOG 115:947-956 (Pubitemid 351841762)
9. Drummond MF, Jefferson TO (1996) Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party BMJ 313:275-283 (Pubitemid 26254740)
10. Drummond M, Sculpher M (2005) Common methodological flaws in economic evaluations. Med Care 43 (7 Suppl): 5-14
11. Drummond M, O'Brien B, Stoddart G, Torrance G (1997) Methods for the economic evaluation of health care programmes, 2nd edn. Oxford University Press, New York
12. Elbasha EH, Dasbach EJ, Insinga RP (2007) Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 13:28-41 (Pubitemid 46057835)
13. Elixhauser A, Luce BR, Taylor WR, Reblando J (1993) Health care CBA/CEA: an update on the growth and composition of the literature. Med Care 31 (7 Suppl): JS1-JS11, JS18-JS149
14. Elixhauser A, Halpern M, Schmier J, Luce BR (1998) Health care CBA and CEA from 1991 to 1996: an updated bibliography. Med Care 36 (5 Suppl): MS1-MS9, MS18-MS147
15. Gerard K, Smoker I, Seymour J (1999) Raising the quality of cost-utility analyses: lessons learnt and still to learn. Health Policy 46:217-238 (Pubitemid 29115071)
16. Gerard K, Seymour J, Smoker I (2000) A tool to improve quality of reporting published economic analyses. Int J Technol Assess Health Care 16(1):100-110 (Pubitemid 30263206)
17. Ginsberg GM, Fisher M, Ben-Shahar I, Bornstein J (2007) Cost-utility analysis of vaccination against HPV in Israel. Vaccine 25:6677-6691 (Pubitemid 47337133)
18. Gonzalez-Perez JG (2002) Developing a scoring system to quality assess economic evaluations. Eur J Health Econ 3:131-136 (Pubitemid 36396513)
19. Higgins J P T, Green S (eds) Cochrane handbook for systematic reviews of interventions version 5.0.0 (updated February 2008). The Cochrane Collaboration, 2008. Available via www.cochrane-handbook.org
20. Hill SH, Mitchell A, Henry D (2000) Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA 283:2116-2121 (Pubitemid 30241307)
21. Insinga RP, Dasbach EJ, Elbasha EH, Puig A, Reynales-Shigematsu LM (2007) Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation. Vaccine 26:128-139 (Pubitemid 350218187)
22. Insinga RP, Dasbach EJ, Allen SE, Carides GW, Myers ER (2008) Reductions in human papillomavirus-disease resource use and costs with quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccination: the FUTURE study economic evaluation. Value Health 11:1022-1032
23. Jefferson T, Demicheli V (2002) Quality of economic evaluations in health care. BMJ 324:313-314 (Pubitemid 34142748)
24. Jit M, Choi YH, Edmunds WJ (2008) Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 337: a769
25. Kulasingam SL, Benard S, Barnabas RV, Largeron N, Myers ER (2008) Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: a costeffectiveness analysis. Cost Eff Resour Alloc 6:4
26. La Torre G, Chiaradia G, Gianfagna F, De Lauretis A, Boccia S, Ricciardi W (2006) Quality assessment in meta-analysis. Ital J Public Health 2:44-50
27. La Torre G, Chiaradia G, de Waure C et al (2007) Health technology assessment and vaccine: new needs and opportunities? Ital J Public Health 4:81-88
28. La Torre G, Chiaradia G, de Waure C, Nicolotti N, Monteduro A, Ricciardi W (2009) Report HTA del vaccino quadrivalente anti-HPV Gardasil (HTA report on quadrivalent HPV vaccine Gardasil). Ital J Public Health 6 (Suppl 2): S1-S66
29. Mennini FS, Giorgi Rossi P, Palazzo F, Largeron N (2009) Health and economic impact associated with a quadrivalent HPV vaccine in Italy. Gynecol Oncol 112:370-376
30. Neumann PJ, Stone PW, Chapman RH, Sandberg EA, Bell CM (2000) The quality of reporting in published cost-utility analyses, 1976-1997. Ann Intern Med 132:964-972 (Pubitemid 30397597)
31. Petrou S, Henderson J, Roberts T, Martin MA (2000) Recent economic evaluations of antenatal screening: a systematic review and critique. J Med Screen 7:59-73
32. Russo P (2008) La valutazione farmacoeconomica nel contesto regolatorio italiano. Analisi quali-quantitativa dei dossier di richiesta del prezzo e della rimborsabilità. (Pharmacoeconomic evaluations in the Italian regulatory context: a quali-quantitative analysis of pricing and reimbursement dossiers). Pharmacoecon Ital Res Artic 10:59-75
33. Siegel JE, Weinstein MC, Russell LB, Gold MR (1996) Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA 276:1339-1341 (Pubitemid 26346934)
34. Szucs TD, Largeron N, Dedes KJ, Rafia R, Bénard S (2008) Costeffectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland. Curr Med Res Opin 24:1473-1483 (Pubitemid 351741581)
35. Thurston SJ, Craig D, Wilson P, Drummond MF (2008) Increasing decision-makers' access to economic evaluations: alternative methods of communicating the information. Int J Technol Assess Health Care 24:151-157 (Pubitemid 351519513)
36. Ungar WJ, Santos MT (2003) The Pediatric Quality Appraisal Questionnaire: an instrument for evaluation of the pediatric health economics literature. Value Health 6(5):584-594 (Pubitemid 37187721)
37. Wallace JF, Weingarten SR, Chiou CF et al (2002) The limited incorporation of economic analyses in clinical practice guidelines. J Gen Intern Med 17:210-220 (Pubitemid 34603849)
38. Weinstein MC, Stason WB (1977) Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 296:716-721 (Pubitemid 8066534)